FDA Warning Letter · #695663
Swisschems — FDA Warning Letter (December 10, 2024)
In plain English
Unapproved drugsFDA said products made or sold by Swisschems, including semaglutide, are unapproved new drugs under federal law.
What it means for you
Unapproved drugs like these have not been reviewed by FDA for safety, quality, or effectiveness. A GLP-1 should come with a prescription and from a state-licensed pharmacy.
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/swisschems-695663-12102024
Letter details
- Company
- Swisschems
- Letter number
- #695663
- Issue date
- December 10, 2024
- Subject
- Unapproved New Drugs/Misbranded
What FDA warning letters mean
A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.
A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.
For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.
What this letter means if you use compounded GLP-1s
A warning letter is not a recall, and it does not by itself mean a product you already have is unsafe, but it does mean the FDA found problems it expects Swisschems to fix. Compounded GLP-1s are not FDA-approved, and the rules for selling them changed when the shortages ended; our explainer on where compounded semaglutide stands with the FDA now covers what is still allowed.
The products in this letter are ones FDA calls unapproved new drugs. For contrast, our semaglutide drug guide page shows the versions that went through FDA review, and which GLP-1s can be compounded explains where the rules draw the line.
Other warning letters in our database
- Xcel Research LLC — December 10, 2024
- Summit Research Peptides — December 10, 2024
- Prime Peptides — December 10, 2024
- Cheap Medicine Shop/www.cheapmedicineshop.com — September 24, 2026
- Online Generic Medicine/www.onlinegenericmedicine.com — September 23, 2026
Editorial Disclaimer
FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- 503B outsourcing facility · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- FDA Warning Letter · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory